Studies have shown that the SCGN-insulin interaction can stabilize insulin, enhance the hypoglycemic activity of insulin in vivo, and reduce hepatic steatosis and cholesterol metabolism disorders (51). This evidence concerns the gene INS and fatty liver disease.